Alembic Pharmaceuticals Ltd has received tentative approval from the US Food and Drug Administration for brexpiprazole tablets in 0.25 mg, 0.5 mg, 1 mg, 2 mg, 3 mg and 4 mg strengths, according to an exchange filing.
The drug is a generic version of Otsuka Pharmaceutical Co Ltd's Rexulti tablets.
It is indicated as adjunctive therapy alongside antidepressants for the treatment of major depressive disorders and schizophrenia.
According to information from IQVIA, the drug's sales for the fiscal year that ended in December 2022 totaled about $1.6 billion.
Oppo K13 Turbo Confirmed To Launch In India On August 11, Will Be Priced Under Rs. 40,000
Mumbai: Elderly Man, Son Attacked For Objecting To Pigeon Feeding In Mira Road Building; 4 Booked
Dhanush & Mrunal Thakur Are Indeed Dating! Actors Have 'No Plans Of Making It Official Anytime Soon', Claims Report
Backbenchers A Thing Of Past? Kerala Govt To Abolish Conventional Row-Wise Seating In State Schools
The shares of the company traded 0.7% higher at ₹515.75 on NSE, at 09:15 IST.
